ANIMAL MODEL OF GLOBOID CELL LEUKODYSTROPHY IN RHESUS MONKEYS: LYSOSOMAL STORAGE
恒河猴球状细胞脑白质营养不良的动物模型:溶酶体储存
基本信息
- 批准号:6116204
- 负责人:
- 金额:$ 16.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-05-01 至 2000-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Globoid cell leukodystrophy is a rare autosomal recessive genetic
disease caused by low levels of B-galactosidase activity, a lysosomal
enzyme important in myelin metabolism. An infant rhesus monkey with
this disease was diagnosed at TRPRC in 1989. Since then, we
intentionally inbred this group of animals and in 1996 observed two
additional affected infants. These two homozygous affected animals
allowed us, in collaboration with Dr. David Wenger, Jefferson Medical
College, Philadelphia, to identify the disease-causing mutation in the
rhesus GALC gene and to unequivocally identify 22 carrier animals by
PCR. The sequence of the rhesus GALC cDNA is 98% identical to the
human, and the deduced amino acid sequence is 97% identical to that of
humans. The mutation responsible for GLD in these monkeys consists of
the deletion of the AC dinucleotide corresponding to cDNA positions
387 and 388. This results in a frame shift, leading to a premature
stop codon. GALC activity was measured in the 2 homozygous affected,
21 normal and 20 carrier monkeys. The 2 affected infants had a GALC
activity less than 2% of normal. The average activity for 21 normal
monkeys was 0.94 nmol/hr/mg of protein, while the average for 20
carriers was 0.53. Psychosine levels in the brains of affected
infants were very high. We established fibroblast and EBV-transformed
lymphocyte cultures from these homozygous infants, and have initiated
in vitro therapeutic studies with retroviral vectors containing the
human GALC gene. We have performed chorionic villus sampling for 3
birth seasons and have accurately diagnosed the genetic status of the
fetuses each year prior to birth. In a related subproject, we have
begun preliminary studies to determine the most appropriate way to
deliver therapeutic genes to affected monkeys. This nonhuman primate
model will be valuable for studies of gene therapy of this and similar
disorders. FUNDING Base Grant, Venture Research PUBLICATIONS Luzi P,
Rafi MA, Victoria T, Baskin GB, Wenger DA. Characterization of the
rhesus monkey galactocerebrosidase (GALC) cDNA and gene, and
identification of the mutation causing globoid cell leukodystrophy
(Krabbe disease) in this primate. Genomics 42:319-324, 1997; Baskin
GB, Ratterree M, Davison BB, Falkenstein KP, Clarke MR, England JD,
Vanier MT, Luzi P, Rafi MA, Wenger DA. Genetic Galactocerebrosidase
deficiency (globoid cell leukodystrophy, Krabbe disease) in rhesus
monkeys. Lab Anim Sci 48:476-
球状细胞白质营养不良是一种罕见的常染色体隐性遗传
由溶酶体B-半乳糖苷酶活性低水平引起的疾病
髓鞘代谢中重要的酶。一只幼年恒河猴
这种疾病是1989年在TRPRC被诊断出来的。从那时起,我们
故意对这群动物进行近亲繁殖,并在1996年观察到两只
其他受影响的婴儿。这两只纯合子感染的动物
允许我们与大卫·温格博士合作,杰斐逊医疗
费城大学,以确定致病突变在
恒河猴GALC基因及明确鉴定22只携带该基因的动物
聚合酶链式反应。恒河猴GALC基因的序列与恒河猴的
推导的氨基酸序列与人的氨基酸序列同源性为97%。
人类。导致这些猴子GLD的突变包括
与cDNA位对应的AC二核苷酸的缺失
387和388。这会导致帧移动,从而导致过早
停止密码子。检测2例受累纯合子的GALC活性,
正常猴21只,携带猴20只。两名受影响的婴儿患有GALC
活动量低于正常的2%。21名正常人的平均活动量
猴子的蛋白质含量为0.94nmol/小时/毫克,而平均为20
携带者为0.53。精神分裂症患者脑组织中的精神药物水平
婴儿都长得很高。我们建立了成纤维细胞和EBV转化
来自这些纯合子婴儿的淋巴细胞培养,并已开始
重组逆转录病毒载体的体外治疗研究
人类GALC基因。我们已经做了3次绒毛取样。
出生季节和准确诊断的遗传状态
每年出生前的胎儿。在一个相关的子项目中,我们有
开始初步研究,以确定最合适的方式
将治疗性基因传递给受影响的猴子。这种非人类的灵长类动物
该模型对这类疾病的基因治疗研究具有一定的参考价值
精神错乱。基金基础补助金,创业研究出版物鲁兹·P,
拉菲·马,维多利亚·T,巴斯金·英格,温格·达尔。刻画人物形象
猕猴半乳脑苷酶(GALC)基因和
球状细胞白质营养不良突变的鉴定
(Krabbe病)在这种灵长类动物身上。基因组学42:319-324,1997;Baskin
GB,Ratterree M,Davison BB,Falkenstein KP,Clarke MR,英格兰JD,
瓦尼尔·MT,卢齐·P,拉菲·马,温格·达尔。遗传性半乳脑苷酶
恒河猴的缺乏症(球状细胞白质营养不良、Krabbe病)
猴子。实验室动画科学48:476-
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GARY B BASKIN其他文献
GARY B BASKIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GARY B BASKIN', 18)}}的其他基金
AAV AS VECTOR FOR TREATMENT OF GLOBOID CELL LEUKODYSTROPHY
AAV 作为治疗球状细胞脑白质营养不良的载体
- 批准号:
6116208 - 财政年份:1999
- 资助金额:
$ 16.14万 - 项目类别:
DEVELOPMENT OF RHESUS MODEL FOR HCV INFECTION: HEPATITIS
HCV 感染:肝炎的恒河猴模型的开发
- 批准号:
6116206 - 财政年份:1999
- 资助金额:
$ 16.14万 - 项目类别:
ANIMAL MODEL FOR GENE THERAPY OF INHERITED DISORDERS
遗传性疾病基因治疗的动物模型
- 批准号:
2908668 - 财政年份:1999
- 资助金额:
$ 16.14万 - 项目类别:
ANIMAL MODEL FOR GENE THERAPY OF INHERITED DISORDERS
遗传性疾病基因治疗的动物模型
- 批准号:
6188461 - 财政年份:1999
- 资助金额:
$ 16.14万 - 项目类别:
IMMUNOSUPPRESSION IN PROLONGING TRANSGENE EXPRESSION: CYSTIC FIBROSIS
延长转基因表达的免疫抑制:囊性纤维化
- 批准号:
6116207 - 财政年份:1999
- 资助金额:
$ 16.14万 - 项目类别:
ANIMAL MODEL OF GLOBOID CELL LEUKODYSTROPHY IN RHESUS: KRABBES DISEASE
恒河猴球状细胞脑白质营养不良的动物模型:克拉布斯病
- 批准号:
6277433 - 财政年份:1998
- 资助金额:
$ 16.14万 - 项目类别:
DEVELOPMENT OF PRECLINICAL MODEL FOR GENE THERAPY USING CD34+ STEM CELLS
使用 CD34 干细胞进行基因治疗的临床前模型的开发
- 批准号:
6247290 - 财政年份:1997
- 资助金额:
$ 16.14万 - 项目类别:
IMMUNOSUPPRESSION IN PROLONGING TRANSGENE EXPRESSION: CYSTIC FIBROSIS
延长转基因表达的免疫抑制:囊性纤维化
- 批准号:
6247291 - 财政年份:1997
- 资助金额:
$ 16.14万 - 项目类别:
PRECLINICAL STUDIES OF LIVER DIRECTED GENE THERAPY IN NON HUMAN PRIMATES
非人类灵长类动物肝脏定向基因治疗的临床前研究
- 批准号:
6247289 - 财政年份:1997
- 资助金额:
$ 16.14万 - 项目类别:
ANIMAL MODEL OF GLOBOID CELL LEUKODYSTROPHY IN RHESUS MONKEYS
恒河猴球状细胞脑白质营养不良动物模型
- 批准号:
6247288 - 财政年份:1997
- 资助金额:
$ 16.14万 - 项目类别:
相似海外基金
The pathogenesis of ALG14-congenital disorders of glycosylation.
ALG14-先天性糖基化障碍的发病机制。
- 批准号:
23K14967 - 财政年份:2023
- 资助金额:
$ 16.14万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identifying New Therapeutics and Molecular Mechanisms in Congenital Disorders of Glycosylation.
确定先天性糖基化疾病的新疗法和分子机制。
- 批准号:
10644811 - 财政年份:2023
- 资助金额:
$ 16.14万 - 项目类别:
Investigating the Genotype-Phenotype Relationships that Underlie Congenital Disorders with Cardiovascular Symptoms through Population-scale Analyses
通过人群规模分析研究具有心血管症状的先天性疾病背后的基因型-表型关系
- 批准号:
10724185 - 财政年份:2023
- 资助金额:
$ 16.14万 - 项目类别:
Identifying understudied protein-related glycoproteome disruption in Congenital Disorders of Glycosylation
识别先天性糖基化障碍中尚未研究的蛋白质相关糖蛋白组破坏
- 批准号:
10725869 - 财政年份:2023
- 资助金额:
$ 16.14万 - 项目类别:
Pathogenic Mechanisms of Congenital Disorders of Glycosylation
先天性糖基化障碍的发病机制
- 批准号:
10633548 - 财政年份:2023
- 资助金额:
$ 16.14万 - 项目类别:
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
- 批准号:
10480649 - 财政年份:2022
- 资助金额:
$ 16.14万 - 项目类别:
Assessment of a potential application of endogenous stem cells to treat congenital disorders
评估内源干细胞治疗先天性疾病的潜在应用
- 批准号:
22K20740 - 财政年份:2022
- 资助金额:
$ 16.14万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
- 批准号:
10616658 - 财政年份:2022
- 资助金额:
$ 16.14万 - 项目类别:
O-glycosylation mechanisms of neurological deficits in congenital disorders of glycosylation
先天性糖基化障碍神经功能缺损的O-糖基化机制
- 批准号:
10040788 - 财政年份:2020
- 资助金额:
$ 16.14万 - 项目类别:
O-glycosylation mechanisms of neurological deficits in congenital disorders of glycosylation
先天性糖基化障碍神经功能缺损的O-糖基化机制
- 批准号:
10250486 - 财政年份:2020
- 资助金额:
$ 16.14万 - 项目类别:














{{item.name}}会员




